Proactive Investors - Run By Investors For Investors

Amryt Pharma to raise €15mln for drug to treat rare skin condition

Rory Nealon, chief financial officer at Amryt Pharma PLC (LON:AMYT), tells Proactive they're raising €15mln in an oversubscribed share placing – partly to fund the pre-launch costs of a drug for a rare skin condition.

Together with existing cash, the proceeds will be used to bankroll the ongoing phase III trial of  AP101, a potential treatment for Epidermolysis Bullosa.

View full AMYT profile View Profile

Amryt Pharma PLC Timeline

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use